Study finds that, for patients already taking antidepressants, activating and/or prohibiting the CB1 receptor in the brain might make those antidepressants more effective.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31ngEPb inside the CED Foundation Archive
To explore related information, click keywords:
Cannabinoid receptors, located throughout the body, are involved in a variety of physiological processes (including appetite, mood, etc.). A 2019 study shows that blocking CB1Rs (cannabinoid receptors that conserve energy) is an effective way to manage metabolic disorders, such as obesity and Type-2 Diabetes.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/31rATuL inside the CED Foundation Archive
To explore related information, click keywords:
It was a privilege to meet with the editor of Wiley Publishing Company’s Alcohol and Drug Abuse Weekly, Dr Peter Grinspoon, and a select group of MA dispensary representatives this weekend, to discuss our shared goals & plan to support global access to education, of physicians, the #MedicalCommunity, the #CannabisIndustry, and the #CannabisCommunity.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2l4sexZ inside the CED Foundation Archive
To explore related information, click the keywords below:
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2HZ6cWb inside the CED Foundation Archive
To explore related information, click keywords:
Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses
In a survey of 30 patients using medical cannabis for a range of illnesses, including Rheumatoid Arthritis, cancer, Hepatitis C, PTSD, and more, patients reported an array of benefits from their cannabis use. Patients successfully used cannabis as an alternative to prescription medication, as a complementary agent with traditional prescription medicines, and to gradually help halt the use of some prescription medications. Benefits described by participants included the effects of cannabis lasting longer than that of opioids, lower risk of addiction, fewer side-effects. Patients also saw their sleep, anxiety, appetite, and adverse reactions improve with the use of medical cannabis. Larger, more controlled studies may suggest cannabis more affirmatively as an alternative or complementary therapy with prescription medications.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2wqDDdQ inside the CED Foundation Archive
To explore related information, click keywords:
Overlaps in pharmacology for the treatment of chronic pain and mental health disorders
Select small trials have demonstrated cannabis to be more effective than other analgesics to treat chronic pain associated with certain conditions. However, the existing research lacks large-scale, controlled experiments relating medical cannabis use to pain management. Additionally, negative effects are documented with respect to cannabis use among adolescents and those suffering from compromised mental health. There is a need for further research on the topic.
View this review (yellow link) or download:
This paper is also stored here: http://bit.ly/2wtvpRY inside the CED Foundation Archive
To explore related information, click keywords:
Medical Cannabis and the Treatment of Obstructive Sleep Apnea: An American Academy of Sleep Medicine Position Statement
Obstructive sleep apnea is a sleep disorder causing episodic airway obstruction that results in the brief “apneic” (cessation of breathing) episodes for brief periods of time. A recent study investigating Dronabinol, a synthetic cannabis derivative, as a potential therapy for sleep apnea resulted in an improvement of 32% in the apnea-hypopnea index. However, the American Academy of Sleep Medicine does not endorse medical cannabis as a treatment for sleep apnea, due to what they point to as a lack of knowledge surrounding the long-term effects of its use. ” Based on these results, cannabis and its components should be further researched to determine its potential for sleep apnea treatment.
This paper is also stored here: http://bit.ly/2YZDTN3 inside the CED Foundation Archive
Dentists’ concerns about the negative effects of cannabis on teeth are legitimate: dry mouth can lead to cavities. It is known that the terpene Delta-3-Carene can dry out bodily fluids (saliva), so avoiding strains w/ high levels can help. http://bit.ly/2KFpp0K
Study shows that cannabis use can contribute to increased risk of treatment-resistant psychosis
